ICU Medical Archives - Page 2 of 2 - Medical Design Sourcing

These 10 medtech companies’ stocks performed best in 2021

(From Ishant Mishra on Unsplash)

Following a year like no other in 2020, 2021 was when many looked to rebound — including the medtech industry.

A number of medtech companies followed up a challenging, pandemic-enveloped year with impressive performances. Plenty of them had already proven in 2020 that they were capable of a quick bounce-back.

Here are 10 medtech companies that saw their stocks soar even higher in 2021:

(This list includes members of the MassDevice MedTech 100 Index of the world’s largest medical device companies. Performance is measured in stock price change from Dec. 31, 2020, to Dec. 31, 2021.)

Get the full story at our sister site, MassDevice.

ICU Medical beats The Street in Q4, posts full-year guidance

ICU Medical (NASDAQ:ICUI) shares rose today on fourth-quarter results that came in ahead of the consensus forecast.

The San Clemente, California-based company posted profits of $19.9 million, or 91¢ per share, on sales of $340.5 million for the three months ended Dec. 31, 2021, for a 23.8% bottom-line slide on sales growth of 6.3%.

Adjusted to exclude one-time items, earnings per share were $1.82, 18¢ ahead of Wall Street, where analysts were looking for sales of $323.9 million.

“Fourth-quarter results were generally in line with our expectations,” ICU Medical CEO Vivek Jain said in a news release.

ICU Medical said it expects to log adjusted EPS of between $9 and $10.50 for the full-year 2022. The company set its adjusted EBITDA guidance for between $450 million and $500 million. The company’s outlook does not reflect the impact of the pending purchase price allocation for the $2.35 billion acquisition of Smiths Medical completed earlier thi…

ICU Medical’s Smiths Medical acquisition remains on track

ICU Medical (NASDAQ:ICUI) is a step closer to acquiring Smiths Medical after clearing a shareholders vote at Smiths’ British parent company, the Smiths Group.

Almost all of the nearly 327 million Smiths Group shareholders voting on November 17 approved the $2.35 billion buy.

Get the full story on our sister site Medical Tubing + Extrusion.

ICU Medical grows profits 24% in Q3 results

ICU Medical (NSDQ:ICUI) this week posted third-quarter results that beat the overall consensus on Wall Street.

The San Clemente, California-based infusion therapy company reported profits of $31 million, or $1.43 per share, on sales of $336 million for the three months ended September 30, for a bottom-line gain of 24.4% on sales growth of 5.49% compared with Q3 2020.

Adjusted to exclude one-time items, earnings per share were $2.07, 27¢ ahead of The Street, where analysts were looking for sales of $314.3 million.

“Third-quarter results were generally in line with our expectations,” CEO Vivek Jain said in a news release.

ICU Medical did not provide a financial outlook for the remainder of the year.

Shares in ICUI were at a standstill in premarket trading.

ICU Medical reports 41% profit increase in Q1

ICU Medical (NSDQ:ICUI) posted first-quarter results yesterday that beat the overall consensus on Wall Street.

The San Clemente, Calif.-based company reported profits of $23.7 million, or $1.09 per share, on sales of $318 million for the three months ended March 31, for a bottom-line gain of 41% on sales losses of -3.21% compared with Q1 2020.

Adjusted to exclude one-time items, earnings per share were $1.62, 12¢ ahead of The Street, where analysts were looking for sales of $300.9 million.

ICU Medical did not provide a financial outlook for the remainder of the fiscal year.

Shares in ICUI were at a standstill before hours today.

ICU Medical dips despite Street-beating Q4

ICU Medical (NSDQ:ICUI) shares took a slight hit today on fourth-quarter results that topped the consensus forecast.

The San Clemente, Calif.-based infusion therapy and critical care technology developer posted profits of $26.1 million, or $1.21 per share, on sales of $320.5 million for the three months ended Dec. 31, 2020, for a 2.7% bottom-line gain on sales growth of 1.6%.

Adjusted to exclude one-time items, earnings per share were $1.77, 26¢ ahead of Wall Street, where analysts were looking for sales of $320.5 million.

“Fourth-quarter results were generally in line with our expectations,” ICU Medical CEO Vivek Jain said in a news release.

ICU Medical said it now expects to log adjusted EPS of between $6.50 and $7.20 for the full year 2021.

ICUI shares were down -2.4% at $212.91 per share in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — w…

ICU Medical shares rise on Street-beating Q2 results

ICU Medical (NSDQ:ICUI) posted second-quarter results that beat the consensus forecast on Wall Street.

The San Clemente, Calif.-based company reported profits of $18.9 million, or 88¢ per share, on sales of $303.4 million for the three months ended June 30, for a bottom-line loss of -17.2% sales loss of -2.8% compared with Q2 2019.

Earnings per share were 88¢, 14¢ ahead of The Street, where analysts were looking for sales of $283.4 million.

“Second quarter results were generally in line with our expectations and reflected strong demand for our infusion pumps due to the COVID-19 pandemic,” CEO Vivek Jain said in a news release.

ICU Medical did not provide a financial outlook for the rest of its fiscal year.

Shares in ICUI were up 6.22% to $190 apiece in pre-market hours.